# Big Health

> Big Health develops self-guided digital cognitive behavioral programs for sleep, anxiety and mood, and FDA-cleared prescription treatments for adult insomnia and generalized anxiety disorder. Founded by Peter Hames and Colin Espie in 2010, it distributes software-based care through employers, health plans, providers and the NHS.

- **Founded:** 2010
- **Headquarters:** San Francisco, United States
- **Founders:** Peter Hames (Co-founder; former CEO), Colin Espie (Co-founder and Chief Scientist)
- **Products:** Sleepio, SleepioRx, Daylight, DaylightRx, Spark Direct
- **Notable:** Sleepio recommended by NICE in May 2022 for specified primary-care use., SleepioRx FDA clearance announced in August 2024., DaylightRx FDA clearance announced in September 2024; FDA database decision dated August 30, 2024.

## Products & services

- **Sleepio** — Self-guided digital CBT-based sleep improvement program, distributed through employer and public-health arrangements; distinct from the US prescription product.
- **SleepioRx** — FDA-cleared prescription digital CBT-I treatment for chronic insomnia and insomnia disorder in adults 18+, alongside usual care.
- **Daylight** — Digital cognitive and behavioral program for worry and anxiety; distinct from DaylightRx.
- **DaylightRx** — FDA-cleared prescription digital CBT treatment for generalized anxiety disorder in adults 22+, alongside usual care.
- **Spark Direct** — Self-paced cognitive and behavioral program for mood, including behavioral activation; not FDA reviewed or approved.
- **SparkRx** — Adolescent depression program acquired with Limbix in 2023; historically aimed at ages 13-22. Do not infer FDA clearance from the Rx name.

## Achievements

- Sleepio recommended by NICE in May 2022 for specified primary-care use.
- SleepioRx FDA clearance announced in August 2024.
- DaylightRx FDA clearance announced in September 2024; FDA database decision dated August 30, 2024.
- National Scottish access to Sleepio and Daylight announced in 2021.
- Company reported more than 750,000 individuals supported in February 2026.

## Latest updates

- **2026-02** — Announced $23.7 million strategic funding co-led by .406 Ventures and AlleyCorp, emphasizing provider adoption and reimbursable prescription treatments.
- **2025-03** — Announced a JAMA study on insomnia and depression symptoms and reported crossing 100 peer-reviewed papers.
- **2024-09** — Announced FDA clearance for DaylightRx.
- **2024-08** — Announced FDA clearance for SleepioRx.
- **2024-04** — Appointed Yael Berman CEO.

## Links

- Website: https://www.bighealth.com/
- LinkedIn: https://www.linkedin.com/company/big-health/
- Twitter/X: https://twitter.com/wearebighealth
- Facebook: https://www.facebook.com/sleepio/

---

Profile page: https://yespress.io/big-health
Published by YesPress — https://yespress.io
Last updated: 2026-10-02